Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2024
0mins
Source: Newsfilter
Clinical Trial Announcement: Adicet Bio, Inc. has opened enrollment for a Phase 1 clinical trial of ADI-270, an allogeneic gamma delta CAR T cell therapy targeting metastatic clear cell renal cell carcinoma (ccRCC), with preliminary data expected in the first half of 2025.
Therapy Details: ADI-270 is designed to target CD70-positive cancers and aims to improve treatment outcomes for patients with solid tumors by overcoming challenges posed by the immunosuppressive tumor microenvironment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACET?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACET
Wall Street analysts forecast ACET stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.890
Low
18.00
Averages
29.33
High
50.00
Current: 7.890
Low
18.00
Averages
29.33
High
50.00
About ACET
Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adicet Bio CEO to Participate in Healthcare Conference
- Conference Participation: Adicet Bio CEO Chen Schor will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, showcasing the company's innovations in autoimmune diseases and cancer.
- Schedule Details: The event is scheduled to start at 7:35 a.m. ET, with a live audio webcast available on Adicet Bio's investor section, allowing investors to stay updated on the company's latest developments.
- Technical Focus: Adicet Bio specializes in developing allogeneic gamma delta T cell therapies, aiming to provide durable treatment effects, particularly showing promise in cancer and autoimmune disease treatments.
- Information Access: An archived replay of the presentation will be available for 30 days post-event, ensuring that investors who cannot attend live can still access relevant information, thereby enhancing communication between the company and its investors.
See More
Adicet Biopress Reports Q1 Earnings Results
- Earnings Beat: Adicet Biopress reported a Q1 GAAP EPS of -$1.88, surpassing market expectations by $1.20, indicating potential improvement in the company's financial performance.
- Cash Position: As of March 31, 2026, the company had $137.6 million in cash, cash equivalents, and short-term investments, down from $158.5 million as of December 31, 2025, reflecting liquidity pressure.
- Funding Outlook: The company expects that its cash and short-term investments as of March 31, 2026, will be sufficient to fund operating expenses into the second half of 2027, indicating financial stability in the near term.
- Historical Financial Data: Adicet Bio's historical GAAP EPS stands at -$2.94, highlighting ongoing challenges in profitability, necessitating attention to future financial improvement strategies.
See More
Adicet Biopress Reports Expanded Net Loss in FY Earnings Release
- Earnings Overview: Adicet Biopress reported a GAAP EPS of -$2.94 for FY 2025, indicating ongoing financial challenges, particularly amid rising R&D and operational costs.
- Net Loss Figures: The net loss for the three months ended December 31, 2025, reached $30.5 million, an increase from $28.7 million in the same period of 2024, reflecting heightened pressures in market competition.
- Stock-Based Compensation Impact: The non-cash stock-based compensation expense included in this report was $5.7 million, significantly up from $3.8 million in 2024, highlighting the company's continued investment in attracting and retaining talent, despite the burden on short-term financial performance.
- Reverse Stock Split Announcement: Adicet Bio announced a one-for-16 reverse stock split aimed at boosting its stock price to meet listing requirements, a strategy that may influence investor confidence and market liquidity.
See More
Johnson & Johnson Reports Positive Phase 2b Results for Lupus Drug Nipocalimab, Plans Phase 3 Trial
- Positive Study Results: Johnson & Johnson's JASMINE study involving 228 systemic lupus erythematosus patients met its primary endpoint, demonstrating statistically significant improvement in patient response rates at Week 24 compared to placebo, marking the first positive results for an investigational FcRn blocker in this indication.
- Safety Profile Consistent: Nipocalimab exhibited a safety and tolerability profile consistent with previous Phase 2 studies, with no new safety signals identified, thereby establishing a solid foundation for further clinical development.
- Significant Market Potential: With systemic lupus erythematosus affecting an estimated 3 to 5 million people globally, including 450,000 in the U.S., the positive study results could provide a strong competitive advantage for Johnson & Johnson in this market.
- Clear Next Steps: Following the positive Phase 2 results, Johnson & Johnson plans to initiate a Phase 3 program for Nipocalimab, aiming to further validate its therapeutic potential in systemic lupus erythematosus, which could drive future revenue growth for the company.
See More
Adicet Bio Announces 1-for-16 Reverse Stock Split to Maintain Listing Compliance
- Reverse Stock Split Plan: Adicet Bio announced a 1-for-16 reverse stock split effective December 30, which will reduce the outstanding shares from approximately 153.3 million to about 9.6 million, enabling the company to regain compliance with the minimum bid price requirement for continued listing.
- Shareholder Approval: The plan was approved by shareholders at a special meeting last week, indicating support for the company's governance and future direction, although this move may lead to short-term stock price volatility.
- Stock Price Impact: Following the announcement, Adicet Bio shares fell by 5.78%, trading at $0.49, reflecting market caution regarding the measure and potentially impacting investor confidence.
- Incentive Plan Adjustments: Proportional adjustments will be made to shares included in the company's equity incentive plans, with no fractional shares issued, aimed at maintaining the effectiveness of employee incentives while ensuring stability in the company's capital structure.
See More
Adicet Bio (ACET) Approves 1-for-16 Reverse Stock Split to Regain Nasdaq Compliance
- Reverse Split Decision: Adicet Bio's board has approved a 1-for-16 reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirement, set to take effect on December 30, 2025, which may negatively impact shareholder confidence.
- Capital Structure Adjustment: This reverse split will reduce the total outstanding shares from approximately 153.3 million to about 9.6 million, and while the par value per share remains unchanged, the decrease in share count could affect market liquidity.
- Shareholder Support: The plan received shareholder approval at a special meeting on December 19, 2025, indicating support for the company's restructuring strategy, despite the current stock price of $0.4766 reflecting an 8.2049% decline from the previous trading day.
- Future Financing Flexibility: The company's authorized share count will remain at 300 million, and the reverse split will increase the number of shares available for future issuance, potentially supporting subsequent financing and business expansion efforts.
See More
Adicet Bio CEO to Participate in Healthcare Conference
- Conference Participation: Adicet Bio CEO Chen Schor will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, showcasing the company's innovations in autoimmune diseases and cancer.
- Schedule Details: The event is scheduled to start at 7:35 a.m. ET, with a live audio webcast available on Adicet Bio's investor section, allowing investors to stay updated on the company's latest developments.
- Technical Focus: Adicet Bio specializes in developing allogeneic gamma delta T cell therapies, aiming to provide durable treatment effects, particularly showing promise in cancer and autoimmune disease treatments.
- Information Access: An archived replay of the presentation will be available for 30 days post-event, ensuring that investors who cannot attend live can still access relevant information, thereby enhancing communication between the company and its investors.
See More
Adicet Biopress Reports Q1 Earnings Results
- Earnings Beat: Adicet Biopress reported a Q1 GAAP EPS of -$1.88, surpassing market expectations by $1.20, indicating potential improvement in the company's financial performance.
- Cash Position: As of March 31, 2026, the company had $137.6 million in cash, cash equivalents, and short-term investments, down from $158.5 million as of December 31, 2025, reflecting liquidity pressure.
- Funding Outlook: The company expects that its cash and short-term investments as of March 31, 2026, will be sufficient to fund operating expenses into the second half of 2027, indicating financial stability in the near term.
- Historical Financial Data: Adicet Bio's historical GAAP EPS stands at -$2.94, highlighting ongoing challenges in profitability, necessitating attention to future financial improvement strategies.
See More
Adicet Biopress Reports Expanded Net Loss in FY Earnings Release
- Earnings Overview: Adicet Biopress reported a GAAP EPS of -$2.94 for FY 2025, indicating ongoing financial challenges, particularly amid rising R&D and operational costs.
- Net Loss Figures: The net loss for the three months ended December 31, 2025, reached $30.5 million, an increase from $28.7 million in the same period of 2024, reflecting heightened pressures in market competition.
- Stock-Based Compensation Impact: The non-cash stock-based compensation expense included in this report was $5.7 million, significantly up from $3.8 million in 2024, highlighting the company's continued investment in attracting and retaining talent, despite the burden on short-term financial performance.
- Reverse Stock Split Announcement: Adicet Bio announced a one-for-16 reverse stock split aimed at boosting its stock price to meet listing requirements, a strategy that may influence investor confidence and market liquidity.
See More
Johnson & Johnson Reports Positive Phase 2b Results for Lupus Drug Nipocalimab, Plans Phase 3 Trial
- Positive Study Results: Johnson & Johnson's JASMINE study involving 228 systemic lupus erythematosus patients met its primary endpoint, demonstrating statistically significant improvement in patient response rates at Week 24 compared to placebo, marking the first positive results for an investigational FcRn blocker in this indication.
- Safety Profile Consistent: Nipocalimab exhibited a safety and tolerability profile consistent with previous Phase 2 studies, with no new safety signals identified, thereby establishing a solid foundation for further clinical development.
- Significant Market Potential: With systemic lupus erythematosus affecting an estimated 3 to 5 million people globally, including 450,000 in the U.S., the positive study results could provide a strong competitive advantage for Johnson & Johnson in this market.
- Clear Next Steps: Following the positive Phase 2 results, Johnson & Johnson plans to initiate a Phase 3 program for Nipocalimab, aiming to further validate its therapeutic potential in systemic lupus erythematosus, which could drive future revenue growth for the company.
See More
Adicet Bio Announces 1-for-16 Reverse Stock Split to Maintain Listing Compliance
- Reverse Stock Split Plan: Adicet Bio announced a 1-for-16 reverse stock split effective December 30, which will reduce the outstanding shares from approximately 153.3 million to about 9.6 million, enabling the company to regain compliance with the minimum bid price requirement for continued listing.
- Shareholder Approval: The plan was approved by shareholders at a special meeting last week, indicating support for the company's governance and future direction, although this move may lead to short-term stock price volatility.
- Stock Price Impact: Following the announcement, Adicet Bio shares fell by 5.78%, trading at $0.49, reflecting market caution regarding the measure and potentially impacting investor confidence.
- Incentive Plan Adjustments: Proportional adjustments will be made to shares included in the company's equity incentive plans, with no fractional shares issued, aimed at maintaining the effectiveness of employee incentives while ensuring stability in the company's capital structure.
See More
Adicet Bio (ACET) Approves 1-for-16 Reverse Stock Split to Regain Nasdaq Compliance
- Reverse Split Decision: Adicet Bio's board has approved a 1-for-16 reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirement, set to take effect on December 30, 2025, which may negatively impact shareholder confidence.
- Capital Structure Adjustment: This reverse split will reduce the total outstanding shares from approximately 153.3 million to about 9.6 million, and while the par value per share remains unchanged, the decrease in share count could affect market liquidity.
- Shareholder Support: The plan received shareholder approval at a special meeting on December 19, 2025, indicating support for the company's restructuring strategy, despite the current stock price of $0.4766 reflecting an 8.2049% decline from the previous trading day.
- Future Financing Flexibility: The company's authorized share count will remain at 300 million, and the reverse split will increase the number of shares available for future issuance, potentially supporting subsequent financing and business expansion efforts.
See More
